Evidence map›Paper›PMID 29784274›Full record

ArticleBioorganic & medicinal chemistry2018

Chiral analogues of (+)-cyclazosin as potent α

Gianni Sagratini, Michela Buccioni, Gabriella Marucci, Elena Poggesi, Matthew Skorski, Stefano Costanzi, Dario Giardinà

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bioorganic & medicinal chemistry, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Identification of a Novel Subtype-Selective αACS chemical neuroscience · 2024
    Article
  2. αInternational journal of molecular sciences · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Gianni SagratiniScuola in Scienze del Farmaco e dei Prodotti della Salute, Università di Camerino, Via S. Agostino 1, 62032 Camerino, Italy. Electronic address: gianni.sagratini@unicam.it.
Michela BuccioniScuola in Scienze del Farmaco e dei Prodotti della Salute, Università di Camerino, Via S. Agostino 1, 62032 Camerino, Italy.
Gabriella MarucciScuola in Scienze del Farmaco e dei Prodotti della Salute, Università di Camerino, Via S. Agostino 1, 62032 Camerino, Italy.
Elena PoggesiDrug Discovery Division, Recordati SpA, Via Civitali 1, 20148 Milano, Italy.
Matthew SkorskiDepartment of Chemistry, American University, Washington, DC 20016, USA.
Stefano CostanziDepartment of Chemistry, American University, Washington, DC 20016, USA; Center for Behavioral Neuroscience, American University, Washington, DC 20016, USA.
Dario GiardinàScuola in Scienze del Farmaco e dei Prodotti della Salute, Università di Camerino, Via S. Agostino 1, 62032 Camerino, Italy.

Funding

Enabling the application of Virtual Screening to GPCR Homology ModelsR15GM119084 · NIGMS · AMERICAN UNIVERSITY · PI COSTANZI, STEFANO · 2016 to 2016
$251k
NIGMS NIH HHS R15 GM119084
6 · The paper itself

Abstract

(+)-Cyclazosin [(+)-1] is one of most selective antagonists of the α

Indexed as

Adrenergic alpha-1 Receptor AntagonistsAnimalsAortaBinding SitesKineticsMaleMolecular Dynamics SimulationProtein Structure, TertiaryQuinazolinesQuinoxalinesRatsRats, WistarReceptors, Adrenergic, alpha-1SpleenStereoisomerismAdrenergic alpha-1 Receptor AntagonistscyclazosinQuinazolinesQuinoxalinesReceptors, Adrenergic, alpha-1(+)-Cyclazosin analoguesα(1)-Adrenoceptor antagonistsα(1)-Adrenoceptor subtypesα(1B)-Adrenoceptor selective antagonists

Identifiers

PMID29784274
PMCPMC6008244

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.